CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Minnesota, University of Chicago Medical Center, Memorial Sloan Kettering Cancer Center, Dartmouth–Hitchcock Medical Center, Dartmouth Cancer Center, Alliance for Clinical Trials in Oncology, University of Kansas, Medical University of South Carolina, Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3135230323